Balancing Creativity with Compliance: Meet Kirsten Searle, Manager of Pharma Development
Discover how Kirsten Searle is enhancing project management excellence at Nanopharm. Hear about her philosophy on balancing pragmatic process with scientific innovation in a fast-paced CRO environment.
Inhaled Generic Bioequivalence Modeling Approaches
Learn how advanced in vitro and in silico modeling help generics companies overcome complex bioequivalence hurdles for orally inhaled drug products (OIDPs).
First Reflections on RDD 2026: FDA Guidance Updates Highlight Progress for NGP pMDIs
Discover first reflections on RDD 2026 from Phoenix, Arizona, highlighting the impact of the research programme funded by FDA and exemplifying Nanopharm’s recognized scientific contributions to supporting the transition to next-generation propellant metered dose inhalers (pMDIs).
From ‘Quality Police’ to Lighthouse Leadership: Transforming QA in Pharma | Nanopharm
Discover how Nanopharm is redefining Quality Assurance as a strategic enabler in drug development. Learn how risk-based QA, innovation, and digital tools are improving outcomes for inhaled and nasal therapies.
Rethinking bioequivalence for nasal suspensions: Adopting an in-vitropathway with confidence
Discover how MDRS provides a regulatory-accepted alternative to clinical endpoint studies for nasal suspension bioequivalence. Learn to de-risk your ANDA pathway today.
Automating pMDI Actuation for Consistent In Vitro Bioequivalence Testing
Discover how automated pMDI actuation improves consistency and reduces analyst variability in in vitro bioequivalence testing, supporting realistic APSD analysis and FDA expectations.
Targeting accelerated progress at the IPAC-RS Nasal Innovation Forum 2025
Explore how Nanopharm presented strategies for accelerating patient-centric nasal product development at the IPAC-RS Nasal Innovation Forum 2025. Dive into key insights on regulatory science, advanced bioequivalence methods, and targeted drug delivery.
Aligning Alternative Bioequivilence with U.S. FDA: Advancing aerosol dose collection to enhance in vitro dissolution studies
Discover how Nanopharm’s DissoHale system advances aerosol dose collection and dissolution testing to support FDA-aligned alternative bioequivalence for OIDPs.
Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques
Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques
GDUFA: FDA adds further weight to modelling and simulation’s role in bioequivalence
GDUFA 2026: FDA strengthens role of modeling & simulation for inhaled generic drug bioequivalence. Learn how this shift enhances efficiency for OINDP development.